The agreement provides Hikma with exclusive rights to market a suite of Hansoh’s injectable oncology medicines within the US for the next five years. Hansoh expects to file these products for approval with the FDA within the next 12 months. 

“Our partnership with Hansoh will expand Hikma’s growing US portfolio of vital injectable oncology medicines and strengthens our ability to serve the growing needs of US hospitals, physicians and patients,” said Daniel Motto, Hikma’s Executive Vice President of Commercial and Business Development. “We look forward to building relationships with Hansoh and other potential partners whose pharmaceutical products can benefit from our strong commercial relationships and our well-established sales and marketing infrastructure.”

“Today one out of every six generic injectable products used in US hospitals is a Hikma product, and we plan to continue adding specialised products like these to our growing portfolio of essential medicines,” said Riad Mechlaoui, Hikma’s President of Injectables.